Table 3 Maximum likelihood analysis of E1690 and E1684
From: Bayesian methods in clinical trials: a Bayesian analysis of ECOG trials E1684 and E1690
Endpoint | Weight (a 0) | Hazard ratio estimate | 95% CI | % Reduction | P-value |
|---|---|---|---|---|---|
RFS | Study covariate | 1.35 | (1.12, 1.63) | 35 | 0.0018 |
Combined | 1.34 | (1.11, 1.62) | 34 | 0.0021 | |
Frailty | 1.35 | (1.12, 1.62) | 35 | 0.0019 | |
OS | Study covariate | 1.15 | (0.93, 1.41) | 14 | 0.196 |
Combined | 1.13 | (0.92, 1.39) | 13 | 0.232 | |
Frailty | 1.14 | (0.93, 1.40) | 14 | 0.200 |